The new Alzheimer's drug Lecanemab is raising great hopes for people with dementia and their caregivers. Very recently, a panel of experts from the European Medicines Agency (EMA) recommended the new active ingredient for treatment – subject to strict conditions. But which patient groups meet the requirements for treatment with Lecanemab? This...
In the second part of our new special newsletter, SCHLAGLICHT – New Dementia Medications, Jana Rühl, a research associate at digiDEM Bavaria, discusses the publication by the research team led by Professor Sören Mattke from the University of Southern California. Today, we address the question of whether healthcare systems can even cope with the diagnostic requirements...
SPOTLIGHT – New Medications for Dementia – this is the name of our new series on new active ingredients for the treatment of Alzheimer's disease. We want to shed „spotlight“ on the multifaceted topic of „New Dementia Medications and Challenges for Everyday Care.“ These new medications are intended for people in the early stages of the disease or in the mild phase...
